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Deeb et al. International Tourette DBS Database – Registry
Tourette Syndrome (TS) is a neuropsychiatric disease characterized by a combination of
motor and vocal tics. Deep brain stimulation (DBS), already widely utilized for Parkinson’s
disease and other movement disorders, is an emerging therapy for select and severe
cases of TS that are resistant to medication and behavioral therapy. Over the last two
decades, DBS has been used experimentally to manage severe TS cases. The results
of case reports and small case series have been variable but in general positive. The
reported interventions have, however, been variable, and there remain non-standardized
selection criteria, various brain targets, differences in hardware, as well as variability in
the programming parameters utilized. DBS centers perform only a handful of TS DBS
cases each year, making large-scale outcomes difficult to study and to interpret. These
limitations, coupled with the variable effect of surgery, and the overall small numbers of
TS patients with DBS worldwide, have delayed regulatory agency approval (e.g., FDA
and equivalent agencies around the world). The Tourette Association of America, in
response to the worldwide need for a more organized and collaborative effort, launched
an international TS DBS registry and database. The main goal of the project has
been to share data, uncover best practices, improve outcomes, and to provide critical
information to regulatory agencies. The international registry and database has improved
the communication and collaboration among TS DBS centers worldwide. In this paper
we will review some of the key operation details for the international TS DBS database
and registry.
Keywords: Tourette syndrome, deep brain stimulation, database, registry, tics, regulatory agencies
INTRODUCTION
Gilles de la Tourette Syndrome (TS) is a neuropsychiatric
disorder characterized by motor and vocal tics. In a subset
of cases, these tics can be severely debilitating (Freeman
et al., 2000; Malaty and Akbar, 2014; Shprecher et al., 2014).
The pathophysiology of TS has been increasingly linked to
dysfunction in a complex basal ganglia thalamo-cortical circuit
(BGTCC) (Da Cunha et al., 2015). Deep brain stimulation
(DBS)—effective for movement disorders including Parkinson’s
disease, dystonia, and tremor—has been explored since 1999 as a
potential therapy for select cases of severe, medication-resistant
TS (Müller-Vahl et al., 2011). However, DBS use in TS is still
considered investigational and has not received regulatory agency
approval.
Initial stereotactic surgical treatment with thalamotomy
for TS was introduced by Rolf Hassler in 1970 (Hassler
and Dieckmann, 1970). Cooper, Hassler, and Dieckmann
were part of surgical teams performing this procedure for
few TS patients. Hassler initially targeted the centromedian-
parafascicular complex. Thus, the selection of the thalamic target
for DBS was motivated by the relative successes of Hassler and
other clinicians applying the thalamotomy procedure in this
brain region.
Despite the initial successes, thalamotomy was never widely
adopted as a treatment for TS. The invasiveness of the procedure,
the issues with accuracy using early stereotaxic equipment,
and the risk of speech, swallowing, and cognitive side effects
due to the large size of the lesions all limited its widespread
use. Three decades later in 1999 Vandewalle and colleagues
implanted DBS electrodes bilaterally in the nucleus ventro-oralis
internus/centromedian-parafascicular complex (Voi/CM/Pf) of
the thalamus (Vandewalle et al., 1999). The Vandewalle groupwas
able to demonstrate the relative safety and potential effectiveness
in a small series of patients published over the next several years.
This initial experience sparked the interest of other groups and
led to a dialogue about the possibility of applying DBS in various
brain targets along the BGTCC.
This interest has been supported by a growing number
of studies in the peer-reviewed literature (Ackermans et al.,
2011; Massano et al., 2013; Jimenez-Shahed, 2015; Kefalopoulou
et al., 2015). These studies reveal generally positive results with
occasional side effects (e.g., hemorrhage, stimulation-induced),
however it should be kept in mind that most studies have
been small and uncontrolled (Duits et al., 2012; Sachdev et al.,
2012; Savica et al., 2012; Ackermans et al., 2013; Dehning et al.,
2014; Kim and Pouratian, 2014; Malaty and Akbar, 2014; Zhang
et al., 2014; Kefalopoulou et al., 2015). Additionally, there were
other important differences in the DBS intervention such as
the brain target (Martínez-Fernández et al., 2011; Viswanathan
et al., 2012), the surgical targeting methods, the type(s) of devices
implanted, the stimulation paradigm (Rotsides and Mammis,
2013), and the baseline disease characteristics (Okun et al.,
2008).
Teams performing DBS have in the past decade explored at
least eight possible brain targets for TS cases (Cavanna et al.,
2011; Porta et al., 2012). These targets have included the thalamic
CM/Pf (Visser-Vandewalle et al., 2003; Maciunas et al., 2007;
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Ackermans et al., 2010, 2011), the subthalamic nucleus, the
posterolateral globus pallidus internus, the anteromedial globus
pallidus internus (Dehning et al., 2008; Massano et al., 2013;
Dong et al., 2014), the globus pallidus externus (Piedimonte et al.,
2013), the nucleus accumbens (Kuhn et al., 2007; Sachdev et al.,
2012), the dorsomedial nucleus of the thalamus, and the anterior
limb of the internal capsule (Flaherty et al., 2005).
Academic medical centers with specialized TS clinics have
collectively reported only a handful of appropriate DBS
candidates presenting for a surgical intervention each year,
rendering it nearly impossible to achieve the statistical power
necessary to draw critical conclusions about DBS therapy in this
population. We therefore aimed to develop an International DBS
Registry and Database for TS with the idea that the statistical
power necessary to refine and improve this procedure could
only be achieved through the collection of a large worldwide
community of cases.
Questions to be answered include best targets, best
phenotypical indications, most appropriate surgical and
programming approaches, efficacy, and other outcomes. There
are many obstacles for investigator initiated device studies as
noted recently by Foote et al (Kelly et al., 2014). This is most
problematic in less common disorders such as TS. Limited
funding and lack of insurance coverage for devices in clinical
trials have created a vicious cycle discouraging investigator-
initiated device trials (Kelly et al., 2014; Rossi et al., 2014). The
TS registry and database has the potential to facilitate a paradigm
shift by collecting important information about TS DBS that
cannot be obtained by using standard clinical trial design. One
important goal of this project is to obtain approval for the
procedure from appropriate regulatory agencies.
REVIEW OF THE LITERATURE
A review of the English language literature was performed
through PUBMED using the medical subheading database
with the keywords “deep brain stimulation” AND “Tourette
syndrome.” The review was focused on original articles and
excluded review articles.
A large number of reports were available, however most were
case reports or small series. A relatively recent article by Motlagh
et al. (2013) reviewed the available published cases. In Table 1,
we summarize the studies reporting a minimum of four TS DBS
patients. We excluded reports with less than four patients.
The most recent TS DBS study appeared in the Lancet
Neurology in June 2015 (Kefalopoulou et al., 2015). It was
a randomized double-blind crossover trial conducted in 15
patients. The target for most patients was the anteromedial
GPi (two were targeted in the posteroventral GPi) and all
subjects were randomly assigned 1:1 to either 3 months of on-
stimulation or 3 months off stimulation. All subjects switched
to the alternative condition. Only 13 of 15 patients completed
the two-blinded assessments. There was a small benefit in tic
reduction as noted by a mean improvement of 12.4 points
(equivalent to 15.3%) on the Yale Global Tic Severity Scale
(YGTSS).
Three other randomized double-blind trials have also been
published. The target was CM/Pf and these studies had smaller
numbers. Maciunas et al. (2007) randomized five patients to
receive bilateral DBS electrode implantation in a single operative
session. There was a standardized follow-up at 17–21 days
following implantation. The first outcome was measured at 7
days, and patients were randomized to stimulation in one of four
combinations (right on, left off; right off, left on; right on, left
on; right off, left off). Each 7 days during a 28-day follow-up
period another randomized outcome was implemented until all
potential conditions were tested. This study procedure was then
followed by 3 months of open label DBS. Tics were assessed by
standardized rating scales and also by independent video analysis.
Unilateral stimulation proved not as effective as bilateral DBS,
and overall there were positive benefits in tic reduction reported
in three of the five patients.
Ackermans et al. (2011) randomized six patients to receive
bilateral DBS electrodes in the Voi/CM/Pf complex of the
thalamus. Patients were assigned to 3 months on stimulation
followed by 3 months off stimulation (group A) or vice-versa
(group B). This crossover period was followed by 6 months of
open label on stimulation. Only one patient was randomized
to group B. There was a significant improvement of 37% in
tics when comparing on vs. off states as well as at comparing
baseline to final outcome. Assessments were performed using the
Yale Global Tic Severity Scale. The authors noted that at 1 year,
patients required more time to finish a selective attention and
response inhibition test (Stroop Color Word Card Test).
Okun et al. (2013) randomized five patients who received
bilateral DBS electrodes in the centromedian complex of the
thalamus. A scheduled stimulation paradigm was used instead
of the conventional continuous stimulation paradigm. Two
patients were randomized to start stimulation at 30 days
from implantation and the remaining three patients to start
stimulation at 60 days from implantation. There was a statistically
significant improvement in YGTSS total score (by 19%) and in
the modified Rush Tic Rating Scale Score. The authors reported
that tic suppression was most effective at deep contacts on the
lead.
All of the studies published reported limitations and
concerns regarding individual variability in outcome, the level of
stimulation required, the effect of tolerance, battery life, electrical
current spread, small sample size, and difficulty in maintaining
the patient blinding.
THE INTERNATIONAL TS DBS REGISTRY
AND DATABASE: GOALS AND DESIGN
The international community collectively responded to the
critical need in the DBS field by collaborating with the
Tourette Syndrome Association (since renamed to the Tourette
Association of America TAA) in 2012 and by launching an
International TS DBS registry and database. The project sought
to consolidate all of the information available for TS DBS cases
worldwide. This effort aimed to shift the field from small case
series and reports to an international large-scale collaborative
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effort. The elements included in the database are summarized in
Figure 1.
This multi-center effort has resulted in the formation of a
registry and a database. There is no restriction on investigators
or groups wishing to join the project, and there is no limitation
to the maximum data necessary to register a case. However,
in order for the case to qualify for database status and
outcome measurement, there must be a minimal amount of
information available to facilitate a group analysis of all of the
participating centers. Additionally, groups with negative as well
as positive experiences with DBS cases are strongly encouraged
to participate. Enrolling all subjects regardless of the quality of
the outcome is mandatory and is an important factor to better
understand the current state of the field.
The database and registry have facilitated networking of
clinician-researchers and have led to the generation of new
hypotheses for both research and care. The database and registry
will provide a repository of valuable information for patient
advocacy groups (e.g., TAA), device manufacturers, as well as
third party payers who are keenly focused on the potential
benefits, burdens, risks, and harms of the therapy.
The registry and database were constructed to collect
information on each case (refer to Figure 1). Currently
supported data have been divided into six categories: (1)
demographic information and disease characteristics, (2) pre-
operative clinical scales (i.e., Yale-Brown obsessive compulsive
scale (YBOCS), YGTSS, Hamilton depression scale, etc.),
(3), surgical procedure data (including brain target, targeting
procedure, lead location, device type, and imaging data), (4)
DBS programming parameters, (5), regular follow-up clinical
assessment and scales, and (6) surgical as well as stimulation-
related adverse events. Electrophysiological data from the DBS
procedure is not currently being collected; however, efforts are
underway to enable for those interested and familiar with the
techniques, intraoperative single cell recordings, and local field
potential (LFP) data extracted from next generation devices
capable of chronic LFP recordings. As these devices become
more widely used, these data will become more available and,
importantly, could add to the insights into the physiology of tic
and the mechanisms underlying DBS-related improvements in
tic behaviors.
CURRENT STATUS OF THE REGISTRY
Participants involved in the database include investigators who
have been implanting TS DBS patients with and without the
intent to publish.
To date 157 patients are registered from 10 different countries.
126 of the patients (80%) are male. The targets used include
the thalamus (92 cases), anteromedial and posteroventral GPi
(61 cases), and the anterior limb of the internal capsule/nucleus
accumbens (2 cases).
The following are the most commonly submitted data:
1. Demographic data
a. Patient identifier
b. Gender
FIGURE 1 | The flowchart reveals the collaborative group’s information collected on each TS DBS case.
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c. Country
d. Age at onset
e. Age at surgery
f. Co-morbidities with a specific focus on obsessive
compulsive disorder (OCD)
g. List of medications tried and at the time of surgery
2. Pre-operative clinical scales
a. YGTSS at baseline
i. Total score
ii. Motor tic subcomponent (less commonly available)
iii. Vocal tic subcomponent (less commonly available)
iv. Impairment subcomponent (less commonly available)
b. YBOCS at baseline
3. Surgical procedure data
a. Lead location and target
b. Device used
4. DBS programming parameters (limited data available at this
point)
5. Follow up clinical assessment and scales
a. YGTSS at 1 year
i. Total score
b. YBOCS at 1 year
6. Adverse events
Another important objective of the database is to track safety.
Many outcomes are collected and these outcomes have been
aligned to the variables potentially necessary for a future
humanitarian device exemption approval by regulatory agencies
in different countries and regions. An adverse event form is
available to participants in the database and was modeled after
requirements from the American Food and Drug Administration
(FDA). Participants have been asked to report all adverse events.
The patient identifier has been used to link the adverse event
to the patient. The following information has been collected:
start date of adverse event, end date of adverse event, weight of
patient at onset of event, outcome of adverse event (resolution,
disability, hospitalization, death), description of the adverse event
and associated relevant history, needed workup and laboratory
studies, DBS hardware information (device name, serial number,
implant date, explant date), and any therapies/surgeries needed
as a result of the adverse event.
UNIQUE CHALLENGES FACING THE TS
REGISTRY AND DATABASE
There are many challenges facing an ambitious initiative,
particularly of this size. One major challenge will be to assure
data quality, particularly given the large number of participating
centers. This challenge has been addressed by process refinement
and feedback of data to the participating centers and sites.
Frequent meetings of participating centers have been a critical
element to improving data quality and also for informing sites
about the minimum data necessary to move from a registration
status to a full database status (submitting data about their
own DBS in TS cases). Additionally, the database has fully
dedicated support for data collection that is headquartered at
the University of Florida Center for Movement Disorders and
Neurorestoration. The central data repository has a full-time
principal investigator (Professor Michael Okun) and a database
manager who together are focused on the mission and objectives,
defining policies and procedures, and assigning responsibilities
for each participant. Additionally, the coordinating center has
defined a clear communication plan, compliance monitoring,
and data policy enforcement.
A more substantial challenge facing this international DBS
registry will be to achieve data uniformity. Several scales exist to
measure tics and each has advantages and limitations. Scales may
assess one or more disease features (i.e., motor tics, vocal tics,
OCD symptoms, and quality of life). There has been variability
among groups in preferences for outcome measures and in time
frames for assessment; standardization of submitted measures
and clinical scales would allow more cases for analysis.
Another important issue facing TS DBS will be to ensure the
database is highly accessible to its contributors and to promote
transparency among investigators. This process if executed
properly has the potential to instill confidence in contributors
and to encourage programs to invest the resources necessary to
obtain the critical measurements necessary for the success of the
project.
STRATEGIES TO ACHIEVE SUCCESS
Several measures have been implemented to counteract potential
database-related problems. One of the cornerstones of success
will be continuous education of the investigators on data
collection. The database has been purposely designed to draw in
as many TS centers in the world participating in DBS operations.
This large-scale effort will increase the number of patients and
expand the potential for multiple data points for later analysis.
Additionally, as centers enroll more patients the hope is that they
will adapt and begin to collect more appropriate and relevant
data-points.
An important strategy is scheduling regular meetings of
the collaborating centers to foster cooperation and to provide
updates on their progress and the obstacles faced. In June
2015, the second annual meeting was convened to discuss the
Tourette database effort and was held at the World Congress
on Tourette Syndrome and Tic Disorders (London, UK). Most
TSA DBS contributors were in attendance and there were
presenters from each country. An image registration initiative
was launched to identify DBS lead locations within the cohort.
The hope was that this initiative would substantially add
to the lead localization images analyzed in conjunction with
already collected information about DBS lead coordinates and
programming parameters. This data may aid in the identification
of the volumes of tissue activation across the targets and would
facilitate the correlation to outcome. Another initiative was to
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locate a health economist to determine what information would
be meaningful to collect across centers. One example of an
immediate use of the data was a question raised at the annual
investigator meeting. The group sought to answer whether
there was an outcome difference between earlier vs. later DBS
implantation. This type of collaborative meetings will be an
important cornerstone for an international database, and the
meetings will continue to create improvement opportunities and
to answer new questions facing the field.
TS REGISTRY AND DATABASE ROLE IN
REGULATORY AGENCY APPROVAL
PROCESSES
Another important goal of the database will be to facilitate
applications to appropriate regulatory agencies worldwide for
approval of TS DBS. This includes regulatory agencies worldwide
such as FDA (USA), CE (EuropeanUnion), PMDS (Japan), SFDA
(China), TGA (Australia), and many other national and regional
regulatory bodies. In the USA, the most likely approval would be
through a FDA humanitarian device exemption given the small
number of patients currently requiring therapy. DBS approval
on a humanitarian basis for obsessive compulsive disorder was
obtained using pooled data from several small n studies. The use
of a database for TS will facilitate an analysis of a larger number
of patients. It will facilitate the collection of important safety data,
a crucial step needed for regulatory agency approval. The multi-
center data collection will encourage a shift to a more uniform
data collection and analysis.
CONCLUSIONS
The international registry and database has been designed to
overcome the severe limitations of small-n studies for TS DBS.
The project has made considerable progress toward a truly global
database. We have now demonstrated proof of principle that
reliable and comprehensive data can be collected. This data will
be used to address fundamental questions facing the TSDBS field,
including identification of optimal brain target(s) for each patient
based on individual symptom profiles, as well as stimulation
parameters for each brain target and/or symptom. Additionally,
a robust dataset will facilitate analysis of important questions
that may potentially inform outcomes such as the relationship
between baseline disease characteristics and the short and long-
term clinical outcome. As data expand we will be able to move
toward more advanced queries that can be used to address
complex questions such as the relationship between electrode
placement and clinical outcomes, as well as the correlation of
lead location to adverse events. These basic, yet critical questions
remain unanswered (Rotsides and Mammis, 2013; Jimenez-
Shahed, 2015). Importantly, the systematic conglomeration
of TS DBS datasets will generate the “higher n” critical to
design clinical trials, power meaningful analyses, and generate
recommendations for patient, target, and stimulation parameter
selection. Finally, the database will be instrumental in applying
for regulatory device exemptions.
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